These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 22508695)

  • 21. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
    Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
    Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T
    Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
    Moreira IS; Fernandes PA; Ramos MJ
    Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor and its inhibitors.
    Verheul HM; Pinedo HM
    Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
    Bikfalvi A; Bicknell R
    Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [VEGF-receptor inhibitors for anti-angiogenesis].
    Shibuya M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
    Niu G; Chen X
    Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging tumor angiogenesis.
    Red-Horse K; Ferrara N
    J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review).
    Taurone S; Galli F; Signore A; Agostinelli E; Dierckx RA; Minni A; Pucci M; Artico M
    Int J Oncol; 2016 Aug; 49(2):437-47. PubMed ID: 27277340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer.
    Yang F; Jin C; Jiang YJ; Li J; Di Y; Fu DL
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):541-9. PubMed ID: 21504321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of Angiogenesis in Cancer Therapy - Synthesis and Biological Activity.
    Gensicka M; Głowacka A; Dzierzbicka K; Cholewinski G
    Curr Med Chem; 2015; 22(33):3830-47. PubMed ID: 26337104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.
    Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH
    J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
    Kieran MW; Kalluri R; Cho YJ
    Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a006593. PubMed ID: 23209176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.